跳转至内容
Merck
CN

1098220

USP

Cefuroxime Axetil

United States Pharmacopeia (USP) Reference Standard

别名:

[6R-[6α,7β(Z)]]-3-[[(Aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(acetyloxy)ethyl ester

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H22N4O10S
化学文摘社编号:
分子量:
510.47
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1

SMILES string

O=C1[C@@H](NC(/C(C2=CC=CO2)=N\OC)=O)[C@]3([H])N1C(C(OC(C)OC(C)=O)=O)=C(COC(N)=O)CS3

InChI key

KEJCWVGMRLCZQQ-YJBYXUATSA-N

grade

pharmaceutical primary standard

API family

cefuroxime

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefuroxime Axetil USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Cefuroxime Axetil for Oral Suspension
  • Cefuroxime Axetil Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Resp. Sens. 1 - Skin Sens. 1

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sruti Jammula et al.
Drug delivery, 22(1), 125-135 (2014-01-15)
Biphasic floating minitablets of cefuroxime axetil were prepared by melt granulation technique using two different grades of gelucire namely 50/13 and 43/01 to maintain constant plasma drug concentration. Loading dose of cefuroxime axetil was formulated as immediate release (IR) minitablets
M A Marx et al.
Drug intelligence & clinical pharmacy, 22(9), 651-658 (1988-09-01)
Cefuroxime axetil is a orally active prodrug formulation of cefuroxime, which upon absorption undergoes immediate deesterification to free cefuroxime. Cefuroxime axetil offers an in vitro antibacterial spectrum against many gram-positive and some gram-negative organisms. Its beta-lactamase stability makes it useful
L J Scott et al.
Drugs, 61(10), 1455-1500 (2001-09-18)
Cefuroxime axetil, a prodrug of the cephalosporin cefuroxime, has proven in vitro antibacterial activity against several gram-positive and gram-negative organisms, including those most frequently associated with various common community-acquired infections. In numerous randomised, controlled trials, 5 to 10 days' treatment
P Gehanno et al.
The British journal of clinical practice, 49(1), 28-32 (1995-01-01)
Recent resurgence in serious streptococcal infections and rising failure rates with the standard 10-day course of therapy with penicillin V for group A beta-haemolytic streptococcus (GABHS)-associated tonsillopharyngitis (pharyngitis and/or tonsillitis) have heightened interest in alternative treatments for this infection. Reasons
H J Manley et al.
Clinical nephrology, 49(4), 268-270 (1998-05-16)
Cefuroxime axetil has been associated with few reported adverse effects. We report a case of bilateral renal cortical necrosis in a female after receiving 7 doses over 4 treatment days. The patient presented with worsening symptoms consisting of arthralgias, pruritus

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持